Purdue Pharma’s New $7.4B Reorganization Plan
Purdue Pharma has submitted a revised reorganization plan designed to distribute more than $7.4 billion in cash to creditors, subject to certain reserves.
The plan aims to compensate opioid crisis victims and fund nationwide abatement programs. This latest effort follows ongoing legal battles over Purdue’s role in the opioid epidemic, with the proposed funds expected to support addiction treatment, prevention initiatives, and affected communities. If approved, the plan could mark a significant step in resolving claims against the company while addressing the broader opioid crisis.